Shots:
- The US FDA has approved Tryvio (12.5mg, oral, QD, with/without food) in addition with antihypertensive drugs to treat hypertensive adults not controlled on other drugs
- The P-III (PRECISION) trial assessed the efficacy of Tryvio for hypertensive adults with SBP ≥140 mmHg receiving at least 3 antihypertensive therapies with the 1EP as change in SiSBP at wk.4 & 2EP as change in SiSBP from wk.36 to wk.40
- In the study post 4wks. PBO run-in duration, patients (n=730) in part 1 were administered Tryvio (12.5mg, 25mg, or PBO, QD) for 4wks., all patients were then administered Tryvio (25mg, QD) for 32wks. in part 2 & post 32wks. patients were re-randomized to receive Tryvio (25mg) or PBO for a 12wk. withdrawal period in part 3
Ref: PRNewswire | Image: Idorsia| Press Release
Related News:- Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) Receives the US FDA’s Approval to Treat NASH with Liver Fibrosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
